Development of the Gene-missile therapy against human malignant gliomas using monocyte as a carrier.
使用单核细胞作为载体开发针对人类恶性胶质瘤的基因导弹疗法。
基本信息
- 批准号:09671431
- 负责人:
- 金额:$ 1.98万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1997
- 资助国家:日本
- 起止时间:1997 至 1998
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The human monocyte chemoattractant protein-1 receptor designated hCCR2 is an essential co-receptor in cell entry by the human immunodeficiency virus as well as a receptor for monocyte chemoattractant protein-1, a member of the family of C-C chemokines that mediate monocyte chemotaxis. To elucidate the molecular mechanisms underlying the transcriptional regulation of hCCR2, we cloned and sequenced the hCCR2 gene ; it was approximately 8 kb in length and consisted of three exons divided by two introns. In the 5'-flanking region, there were the typical mammalian promoter consensus elements, a CAAT box and a TATA box, resulting in a single transcription initiation site. In addition, we found clustered tissue-specific cis-regulatory elements such as GATA consensus sequences, Oct-1 binding sequences, and CAAT/enhancer-binding protein binding sequences. Luciferase assays with various promoter deletions and gel mobility shift assays indicated that three cis-regulatory elements located within the region from -89 to +118 are required for basal activity in THP-1 cells. One element is an octamer sequence 36-bp upstream from the TATA box ; it binds mainly to Oct-1 and is capable of increasing transcriptional activity. The other two elements, which are tandem recognition sites of the CAAT/enhancer-binding protein family, are located in the 5'-untranslated region and account for the transcriptional activation as well as the tissue specificity of hCCR2.
命名为hCCR 2的人单核细胞趋化蛋白-1受体是人免疫缺陷病毒进入细胞中的必需辅助受体,也是单核细胞趋化蛋白-1的受体,单核细胞趋化蛋白-1是介导单核细胞趋化性的C-C趋化因子家族的成员。为了阐明hCCR 2转录调控的分子机制,我们克隆并测序了hCCR 2基因;它的长度约为8 kb,由三个外显子和两个内含子组成。在5 '侧翼区,存在典型的哺乳动物启动子共有元件,CAAT盒和TATA盒,导致单个转录起始位点。此外,我们还发现了成簇的组织特异性顺式调控元件,如加塔共有序列、Oct-1结合序列和CAAT/增强子结合蛋白结合序列。不同启动子缺失的荧光素酶分析和凝胶迁移率变化分析表明,位于-89至+118区域内的三个顺式调节元件是THP-1细胞中基础活性所需的。一个元素是一个八聚体序列36 bp上游的TATA框,它主要结合到Oct-1,是能够增加转录活性。另外两个元件是CAAT/增强子结合蛋白家族的串联识别位点,位于5 '-非翻译区,负责hCCR 2的转录激活以及组织特异性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Takeshima,H.et al.: "Monocyte chemoattractant protein-1(MCP-1)derived from human malignant glioma.-Biological meanings of its expression and application for the treatment of malignant glioma." Research Trends. (in press). (1999)
Takeshima,H.et al.:“源自人恶性神经胶质瘤的单核细胞趋化蛋白-1(MCP-1)。-其表达的生物学意义及其在治疗恶性神经胶质瘤中的应用。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
竹島秀雄,他: "ヒト単球遊走因子受容体の発現調節機構の解明" 神経免疫研究. 10. 142-145 (1997)
Hideo Takeshima 等:“阐明人单核细胞趋化因子受体表达的调节机制”《神经免疫学研究》10. 142-145 (1997)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yamamoto,K.,Takeshima,H.,et al.: "Cloning and functional characterization of the 5'-flanking region of the human monocyte chemoattractant protein-1 receptor(CCR2)gene." J.Biol.Chem.274・8. 4646-4654 (1999)
Yamamoto, K.、Takeshima, H. 等:“人单核细胞趋化蛋白 1 受体 (CCR2) 基因 5 侧翼区域的克隆和功能表征。J.Biol.Chem.274・8” .4646-4654 (1999)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Takeshima, H., Kuratsu, J., Yamamoto, K., Nishi, T., Yamashiro, S., Ushio, Y., and Yoshimura, T.: "Monocyte chemoattractant protein-1 (MCP-1) derived from human malignant glioma. -Biological meanings of its expression and application for the treatment of
Takeshima, H.、Kuratsu, J.、Yamamoto, K.、Nishi, T.、Yamashiro, S.、Ushio, Y. 和 Yoshimura, T.:“源自人类的单核细胞趋化蛋白-1 (MCP-1)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yamamoto, K., Takeshima, H., Hamada, K., Nakao, M., Kino, T., Nishi, T., Kochi, M., Kuratsu, J., Yoshimura, T., Ushio, Y.: "Cloning and functional characterization of the 5'-flanking region of the human monocyte chemoattractant protein-1 receptor (CCR2) g
Yamamoto, K.、Takeshima, H.、Hamada, K.、Nakao, M.、Kino, T.、Nishi, T.、Kochi, M.、Kuratsu, J.、Yoshimura, T.、Ushio, Y.:
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TAKESHIMA Hideo其他文献
TAKESHIMA Hideo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TAKESHIMA Hideo', 18)}}的其他基金
Identification of the novel molecular marker for oligodendroglial tumor using induced differentiation system against glioma stem cell.
使用针对神经胶质瘤干细胞的诱导分化系统鉴定少突胶质细胞肿瘤的新型分子标记。
- 批准号:
20390387 - 财政年份:2008
- 资助金额:
$ 1.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mechanisms underlying inhibition of tumor-immunology in malignant glioma and development of immune-activation therapy using suicide-chimeric molecule
恶性胶质瘤肿瘤免疫抑制机制及自杀嵌合分子免疫激活疗法的开发
- 批准号:
17390405 - 财政年份:2005
- 资助金额:
$ 1.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of the clinical diagnosis and treatment of CNS germinoma using KIT as a target
以KIT为靶点的中枢神经系统生殖细胞瘤临床诊治进展
- 批准号:
15591536 - 财政年份:2003
- 资助金额:
$ 1.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of chemokine-cocktail therapy against hyman malignant gliomas using lymphocyte-specific chemokines
使用淋巴细胞特异性趋化因子开发针对海曼恶性胶质瘤的趋化因子混合物疗法
- 批准号:
13671451 - 财政年份:2001
- 资助金额:
$ 1.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of NF2 tumor suppressor gene promoter in the tumorigenesis
NF2抑癌基因启动子在肿瘤发生中的作用
- 批准号:
11671371 - 财政年份:1999
- 资助金额:
$ 1.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
cGAS-STING通路调控单核细胞活化参与Graves病发病的机制研究
- 批准号:82370787
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
CCL8介导ALA光动力治疗皮肤鳞状细胞癌的效应与机制研究
- 批准号:81602396
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
小胶质细胞的IL-6/JAK/STAT3/MCP-1信号途径在MS/EAE发病过程中的作用
- 批准号:81070958
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Signaling mediators of CCL2/CCR2 and natural product discovery
CCL2/CCR2 信号传导介质和天然产物发现
- 批准号:
10623540 - 财政年份:2023
- 资助金额:
$ 1.98万 - 项目类别:
Regulation and function of CCR2 on T cells in Rheumatoid Arthritis
CCR2对类风湿性关节炎T细胞的调控及功能
- 批准号:
10672641 - 财政年份:2023
- 资助金额:
$ 1.98万 - 项目类别:
Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart Transplantation
剖析供体 CCR2-巨噬细胞在心脏移植后急性细胞排斥过程中的作用
- 批准号:
10449753 - 财政年份:2022
- 资助金额:
$ 1.98万 - 项目类别:
Dissecting the Role of Donor CCR2- Macrophages During Acute Cellular Rejection After Heart Transplantation
剖析供体 CCR2-巨噬细胞在心脏移植后急性细胞排斥过程中的作用
- 批准号:
10597230 - 财政年份:2022
- 资助金额:
$ 1.98万 - 项目类别:
Molecular Imaging CCR2 Lung Inflammation and Fibrosis
分子影像 CCR2 肺部炎症和纤维化
- 批准号:
10343745 - 财政年份:2021
- 资助金额:
$ 1.98万 - 项目类别:
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma
CCL2 和 CCR2 作为髓母细胞瘤的转移驱动因素和治疗靶点
- 批准号:
10543072 - 财政年份:2021
- 资助金额:
$ 1.98万 - 项目类别:
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma
CCL2 和 CCR2 作为髓母细胞瘤的转移驱动因素和治疗靶点
- 批准号:
10320941 - 财政年份:2021
- 资助金额:
$ 1.98万 - 项目类别:
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子
- 批准号:
10380283 - 财政年份:2021
- 资助金额:
$ 1.98万 - 项目类别:
Molecular Imaging CCR2 Lung Inflammation and Fibrosis
分子影像 CCR2 肺部炎症和纤维化
- 批准号:
10543473 - 财政年份:2021
- 资助金额:
$ 1.98万 - 项目类别:
Polarizing Macrophages to Tumor Suppressors by Blocking Multiple CCR2 Chemokine Receptor Epitopes
通过阻断多个 CCR2 趋化因子受体表位将巨噬细胞极化为肿瘤抑制因子
- 批准号:
10328882 - 财政年份:2020
- 资助金额:
$ 1.98万 - 项目类别: